New drug significantly reduces LDL-C cholesterol

A new pooled analysis of heterozygous familial hypercholesterolaemia (HeFH) patients included in the ODYSSEY clinical trial programme found that alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C).  The results were announced at the ESC Congress 2015 in London, and the 78 week results from two of the four trials included in the analysis, ODYSSEY FH I and II, were concurrently published online in the European Heart Journal.  The analysis included 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with alirocumab had an